多巴胺激动剂普拉米醇阻止了勒夫卢诺米德的毒性:对TLR4驱动的炎症和PI3K/Akt抑制的双重打击
Aya M Mustafa1, Nada H Aljarba2, George D Zouganelis3
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, Badr City, 11829, Cairo, Egypt.
European journal of pharmacology
|October 18, 2025
概括
普拉米佩克索尔在保护脏免受莱夫卢诺米德诱导的损伤方面表现有前途. 这项研究发现,普拉米醇通过在小鼠模型中减少炎症和氧化应激来抵消莱夫卢诺米德的毒性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫学 免疫学 免疫学
背景情况:
- 勒弗卢诺米德是自身免疫性疾病的免疫抑制剂,可导致损伤 (毒性).
- 预防勒夫卢诺米德诱导的损伤的有效治疗方法有限.
- 普拉米醇是一种多巴胺激动剂,具有抗炎作用.
研究的目的:
- 调查普拉米佩克索尔在小鼠中对勒夫卢诺米德诱导的损伤的保护潜力.
- 阐明普拉米醇脏保护作用背后的分子机制.
主要方法:
- 使用了一种慢性勒诺米德暴露的小鼠模型.
- 评估了功能,氧化应激,炎症和亡标志物.
- 分析了包括TLR4/MyD88/TRAF6,PI3K/Akt和NF-κB在内的关键信号通路.
- 使用Wortmannin.in证实了PI3K/Akt信号传递的作用.
主要成果:
- 勒弗卢诺米德通过TLR4/MyD88/TRAF6诱导功能障碍,氧化应激,炎症和亡,并抑制PI3K/Akt.
- 普拉米醇治疗逆转了这些影响,减少了NF-κB信号传递,增强了PI3K/Akt激活.
- 普拉米佩克索尔上调了Nrf2抗氧化反应和调节了亡标记物 (Bax,Bcl-2,caspase-3).
- 普拉米醇还降低了IL-17和CD4+T细胞的激活,减少了脏免疫病理.
结论:
- 普拉米佩克索尔显示出显著的脏保护潜力,防止勒夫卢诺米德诱导的脏毒性.
- 保护作用通过抑制炎症途径 (NF-κB,IL-17) 和激活抗氧化剂和生存途径 (Nrf2,PI3K/Akt) 来实现.
- 普拉米佩克索尔是一种潜在的治疗策略,用于管理与莱夫卢诺米德相关的损伤.
相关概念视频
01:24Parkinson's Disease: Treatment
972
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
972
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
814
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
814
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
483
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483
01:28Drug Therapy
239
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
239
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K